JP2023552919A5 - - Google Patents
Info
- Publication number
- JP2023552919A5 JP2023552919A5 JP2023552151A JP2023552151A JP2023552919A5 JP 2023552919 A5 JP2023552919 A5 JP 2023552919A5 JP 2023552151 A JP2023552151 A JP 2023552151A JP 2023552151 A JP2023552151 A JP 2023552151A JP 2023552919 A5 JP2023552919 A5 JP 2023552919A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- ryk
- item
- antibody derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112616P | 2020-11-11 | 2020-11-11 | |
| US63/112,616 | 2020-11-11 | ||
| PCT/US2021/058491 WO2022103705A1 (en) | 2020-11-11 | 2021-11-08 | Antibody variants against wnt receptor ryk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552919A JP2023552919A (ja) | 2023-12-19 |
| JP2023552919A5 true JP2023552919A5 (cg-RX-API-DMAC7.html) | 2024-10-24 |
Family
ID=81601681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023552151A Pending JP2023552919A (ja) | 2020-11-11 | 2021-11-08 | Wnt受容体rykに対する抗体バリアント |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230416375A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4244259A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023552919A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230107628A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117295767A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021380681A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201419A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202233683A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022103705A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3039910A1 (en) | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Anti-ryk antibodies and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL362324A1 (en) * | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| EP2188310B1 (en) * | 2007-08-03 | 2017-02-08 | Genentech, Inc. | Humanized anti-fgf19 antagonists and methods using same |
| US9062101B2 (en) * | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US9228023B2 (en) * | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
| US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| WO2014161037A1 (en) * | 2013-04-03 | 2014-10-09 | Peter Maccallum Cancer Institute | Antibodies against human ryk and uses therefor |
| MA41480A (fr) * | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | Anticorps qui se lient au ccr6 et leurs utilisations |
| AU2016271111B2 (en) * | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| CA3039910A1 (en) * | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Anti-ryk antibodies and methods of using the same |
| BR112019017628A2 (pt) * | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| GB201707561D0 (en) * | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
-
2021
- 2021-11-08 CN CN202180089301.4A patent/CN117295767A/zh active Pending
- 2021-11-08 US US18/035,407 patent/US20230416375A1/en active Pending
- 2021-11-08 AU AU2021380681A patent/AU2021380681A1/en active Pending
- 2021-11-08 KR KR1020237019599A patent/KR20230107628A/ko active Pending
- 2021-11-08 JP JP2023552151A patent/JP2023552919A/ja active Pending
- 2021-11-08 EP EP21892641.8A patent/EP4244259A4/en active Pending
- 2021-11-08 WO PCT/US2021/058491 patent/WO2022103705A1/en not_active Ceased
- 2021-11-08 CA CA3201419A patent/CA3201419A1/en active Pending
- 2021-11-11 TW TW110141972A patent/TW202233683A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102291971B1 (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| KR102366682B1 (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| TWI432451B (zh) | 新穎之抗igf-ir抗體及其用途 | |
| KR102308493B1 (ko) | 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2022023182A (ja) | 脱髄障害の治療のための併用療法および使用 | |
| JP6955721B2 (ja) | RGMa結合タンパク質及びその使用 | |
| FR2888850A1 (fr) | Nouveaux anticorps anti-igf-ir et leurs applications | |
| JP7742433B2 (ja) | 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法 | |
| JP2020522512A5 (cg-RX-API-DMAC7.html) | ||
| Kanno et al. | Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis | |
| JP2023159355A (ja) | Eltd1に対するモノクローナル抗体及びその使用 | |
| CN114945592A (zh) | 抗-α-突触核蛋白单克隆抗体及其使用方法 | |
| CN111789954B (zh) | 延缓衰老的方法和药物 | |
| CN118946581A (zh) | 特异性结合api5蛋白的抗体 | |
| EP4082574A1 (en) | Agent for preventing or treating acute-phase neuromyelitis optica | |
| RU2822199C2 (ru) | Способ предупреждения или лечения периферической нейропатии или боли, сопровождающей заболевание, при котором выявлена периферическая нейропатия или нарушение астроцитов | |
| WO2025254163A1 (ja) | 抗cadm1抗体およびその抗原結合断片 | |
| HK40118760A (en) | Antibodies that specifically bind to api5 protein | |
| KR20260062948A (ko) | Ctla4/tigit 결합 단백질 및 이의 의학적 용도 | |
| KR20240063995A (ko) | 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링 | |
| CN120112560A (zh) | 用于治疗癌症的抗bssl抗体 | |
| CN110291110A (zh) | 特异性结合pauf蛋白的抗体及其用途 |